Irvine, CA – February 3, 2026 – Johnson & Johnson is showcasing a series of innovations in atrial fibrillation (AFib) treatment, alongside new clinical evidence, at the 31st Annual AF Symposium in Boston this week. The company is presenting data from eleven accepted abstracts, highlighting updates to its Pulsed Field Ablation (PFA) and Ultrasound portfolios, and reinforcing its commitment to advancing care for patients with AFib.
A key development is the introduction of the VARIPULSE Plus Platform, an update to Johnson & Johnson’s PFA technology. This platform incorporates automated irrigation flow, designed to enhance procedural confidence while maintaining the established safety profile of the VARIPULSE system. The VARIPULSE Platform is the first PFA technology designed to integrate ablation and mapping through a single workflow with the CARTO 3 System, aiming for increased precision, efficiency, and reproducibility in AFib treatment.
Johnson & Johnson is also announcing the full commercial release of the NUVISION NAV Ultrasound Catheter, described as the world’s first 4D intracardiac imaging catheter fully integrated with a 3D electroanatomical mapping system. Integrated with the CARTO 3 System, the NUVISION NAV is intended to deliver real-time 4D intracardiac imaging to improve anatomical visualization, support precise navigation, and guide complex electrophysiology (EP) procedures with minimal catheter manipulation and potentially reduced fluoroscopy use.
“Evidence-based innovation is the foundation of how we advance arrhythmia care,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “The data and technology updates we are sharing at AF Symposium demonstrate how we are continuously strengthening our electrophysiology portfolio. These technology advancements and upcoming iterations are built on our scientific foundation and will continue raising the bar for AFib ablation.”
Several data presentations are scheduled throughout the symposium. A late-breaking presentation on will focus on outcomes from the Omny-AF Single-Arm Pilot Study, examining pulse field ablation with a large-tip focal catheter and 3D mapping integration. Poster presentations will cover topics including reduced neurovascular events following workflow and irrigation adjustments with the variable loop PFA catheter, the acute safety profile of the variable-loop circular catheter in patients with paroxysmal and persistent AFib as evaluated in the REAL AF Registry, early results from the Variable Loop Circular Catheter Safety Survey (VariSure), and irrigation flow optimization during pulsed field ablation. Another poster presentation will examine the use of 4D intracardiac echo versus transesophageal echocardiography for guidance during left atrial appendage occlusion.
Beyond data presentations, Johnson & Johnson will host educational programs, in-booth presentations, and training opportunities. Experts will lead hands-on sessions utilizing the CARTO 3 System, allowing attendees to experience the VARIPULSE Plus Platform’s automated irrigation-flow control and the NUVISION NAV Ultrasound Catheter in simulated procedures.
The company’s commitment to innovation in AFib treatment is underscored by its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS), announced in December 2025. This registry will capture real-world data on pulsed field ablation (PFA) procedures, aiming to generate clinical insights and improve outcomes. Johnson & Johnson also unveiled results from the VARIPURE substudy of SECURE in September 2025, demonstrating a strong safety profile and high acute effectiveness of the VARIPULSE™ Platform in pulsed field ablation procedures.
In March 2024, Biosense Webster, a Johnson & Johnson subsidiary, filed for Food and Drug Administration approval of the Varipulse pulsed field ablation platform, based on a study that found 80% of patients were free from atrial fibrillation-related symptoms after one year.
Johnson & Johnson’s cardiovascular solutions portfolio encompasses mapping and navigation technologies, miniaturized devices, and precise ablation techniques, addressing conditions such as heart failure, coronary artery disease, stroke, and atrial fibrillation. The company states it is a global leader in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, and an emerging leader in neurovascular care.
Footnotes from Johnson & Johnson materials indicate that Dr. Sharma, Dr. Mansour, Dr. Jazayeri, Dr. Porterfield, Dr. Zou, and Dr. Weisman all served as study investigators and consultants for Johnson & Johnson, but were not compensated for their authorship contributions.
